Framework for assessment of economic feasibility of voltage sag mitigation solutions

Current practices of power quality mitigation in the industry are characterized by sub-optimal investment decisions where over compensation is often the norm such causing huge wastage in financial resources. Providing power quality management services to industrial customers in the form of power quality contracts could yield substantial return for the network operator. With better understanding of network parameters, and the option of installing network level mitigation devices, network operators could employ wider range of cost effective mitigation solutions. Tapping into the market however, entails bearing the risks for the customers which network operators are not always willing or encouraged to do. With potentially millions at stake, extensive risk assessments are crucial for any proposed power quality management scheme. This thesis investigates the voltage sag aspect of the problem as part of a larger power quality management scheme. The aim is to develop general framework for technical and financial assessments of voltage sags prior to the introduction of power quality management service. The thesis focuses on five major aspects of voltage sag assessment: identification of customer requirement, financial loss assessment, network sag performance estimation, sag mitigation, and financial appraisal of mitigating solutions. The first part of the thesis gives a comprehensive overview of current power quality problems faced by industrial customers and provides ranges of typical financial losses incurred by different types of industries around the world. It then proposes robust methodology for assessment of typical financial loss, i.e., customized customer damage function (CCDF), for a given industry based on available survey data and taking into account characteristics of the assessed customer plant. For failure and financial risk assessments, the thesis introduces new customer models employing probabilistic methods to quantify risks induced by voltage sags and proposes generic models that incorporate full flexibility in failure risk assessment, taking into account the effect of unbalanced sags on equipment behavior. It further quantifies the error introduced by sag performance estimation using limited monitoring data with a case study on actual sag profile. It demonstrates how different estimation methods and different durations of monitoring period affect accuracy of estimation of voltage sag profile and associated risk of industrial process failure. Following this, the thesis presents new models for plant and network level sag mitigation devices. They include power injecting mitigation devices, devices that reduce number of faults in the network and devices that reduce the severity of faults. Developed models are then used to investigate the cost-effectiveness of sag mitigation at different levels. Finally, the thesis presents Genetic Algorithm based methodology for deciding on optimal investment scheme in voltage sag mitigation in the network. The sensitivity of the solution to various influential parameters, including plant type and size, sensitive equipment type, process characteristics, financial loss resulting from process interruption, cost and effectiveness of mitigating solution and network fault rates is also established.EThOS - Electronic Theses Online ServiceGBUnited Kingdo

Potential Therapeutic Role of Hispidulin in Gastric Cancer through Induction of Apoptosis via NAG-1 Signaling

Gastric cancer is one of the most common malignant cancers due to poor prognoses and high mortality rates worldwide. However, an effective chemotherapeutic drug without side effects remains lacking. Saussurea involucrata (SI) Kar. et Kir., also known as snow lotus, grows in mountainous rocky habitats at 2600 m elevation in the Tian Shan and A’er Tai regions of China. The ethyl acetate extract of SI had been shown to inhibit proliferation and induce apoptosis in various tumor cells. In this study, we demonstrated that Hispidulin, active ingredients in SI, inhibits the growth of AGS gastric cancer cells. After Hispidulin treatment, NAG-1 remained highly expressed, whereas COX-2 expression was downregulated. Flow cytometric analysis indicated that Hispidulin induces G1/S phase arrest and apoptosis in time- and concentration-dependent manners. G1/S arrest correlated with upregulated p21/WAF1 and p16 and downregulated cyclin D1 and cyclin E, independent of p53 pathway. In addition, Hispidulin can elevate Egr-1 expression and ERK1/2 activity, whereas ERK1/2 inhibitor markedly attenuated NAG-1 mediated apoptosis. Taken together, Hispidulin can efficiently activate ERK1/2 signaling followed by NAG-1 constitutive expression and trigger cell cycle arrest as well as apoptosis in cancer cell. It can be a potential compound for combination therapy of gastric cancer in the future

Impact of COVID-19 Vaccination on Healthcare Worker Infection Rate and Outcome during SARS-CoV-2 Omicron Variant Outbreak in Hong Kong

Immune escape is observed with SARS-CoV-2 Omicron (Pango lineage B.1.1.529), the predominant circulating strain worldwide. A booster dose was shown to restore immunity against Omicron infection; however, real-world data comparing mRNA (BNT162b2; Comirnaty) and inactivated vaccines’ (CoronaVac; Sinovac) homologous and heterologous boosting are lacking. A retrospective study was performed to compare the rate and outcome of COVID-19 in healthcare workers (HCWs) with various vaccination regimes during a territory-wide Omicron BA.2.2 outbreak in Hong Kong. During the study period from 1 February to 31 March 2022, 3167 HCWs were recruited, and 871 HCWs reported 746 and 183 episodes of significant household and non-household close contact. A total of 737 HCWs acquired COVID-19, all cases of which were all clinically mild. Time-dependent Cox regression showed that, compared with two-dose vaccination, three-dose vaccination reduced infection risk by 31.7% and 89.3% in household contact and non-household close contact, respectively. Using two-dose BNT162b2 as reference, two-dose CoronaVac recipient had significantly higher risk of being infected (HR 1.69 p < 0.0001). Three-dose BNT162b2 (HR 0.4778 p< 0.0001) and two-dose CoronaVac + BNT162b2 booster (HR 0.4862 p = 0.0157) were associated with a lower risk of infection. Three-dose CoronaVac and two-dose BNT162b2 + CoronaVac booster were not significantly different from two-dose BNT162b2. The mean time to achieve negative RT-PCR or E gene cycle threshold 31 or above was not affected by age, number of vaccine doses taken, vaccine type, and timing of the last dose. In summary, we have demonstrated a lower risk of breakthrough SARS-CoV-2 infection in HCWs given BNT162b2 as a booster after two doses of BNT162b2 or CoronaVac